Background
Cellulitis is an acute, subacute or chronic inflammation of the dermis and subdermal tissues in which an infective, generally bacterial cause is assumed or proven [1] . It is on a spectrum of disease from mild infections, easily treatable with oral antibiotics, to severe necrotizing infections with associated high mortality [2] . Although a different entity, the term cellulitis is often used interchangeably with erysipelas [1] , is known as 'localized phlegmon' in Germany [3] and falls under the umbrella term of 'skin and soft tissue infections' (SSTI).
Data on the epidemiology of cellulitis and other SSTIs in emergency departments (EDs), particularly in the European setting, are lacking [1, 4] . However, it represents a significant healthcare burden in terms of bed occupancy and economic costs. In 2009, in Ireland, 10 465 patients were admitted to hospital with cellulitis, of whom 9716 were admitted through the ED [5] . In the Netherlands, cellulitis and erysipelas accounted for 3500 hospitalizations in 1999-2001, with an average length-ofstay of 12.1 days and an average cost of h5300 per patient [6] . In a point-prevalence study of European hospitals, cellulitis was found to be among the second most common indication for inpatient antibiotic therapy after respiratory tract infection [7] . Incidence data from the North American setting is more readily available, where it is estimated that cellulitis represents between 1.3 and 3.0% of ED visits [8, 9] .
Although cellulitis may be treated by clinicians of many different specialities, emergency physicians commonly prescribe oral antibiotics for the outpatient treatment of cellulitis and other SSTI [4, 9] . Schrock et al. [9] , in a retrospective study of the factors predictive of observation unit treatment failure in 2005, found that SSTIs (specifically cellulitis, abscess, furuncle, carbuncle, lymphadenitis and pilonidal abscess) accounted for 1.5% of all ED attendances, with 56.2% of patients discharged on oral treatment. Clearly, knowledge of the evidence-based Trial registration: This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on 10th of October 2011, Trial identification number CRD42011001577. treatment of this condition is pertinent to the emergency setting.
The single 'best treatment' for cellulitis is not known [1] . Flucloxacillin, either alone or in combination with penicillin V or its intravenous form, benzylpenicillin, is commonly prescribed, particularly in Ireland and the UK [10] [11] [12] . Furthermore, the British National Formulary [13] , textbooks [14] and local hospital guidelines provide conflicting information on whether oral monotherapy with flucloxacillin or dual therapy with combined flucloxacillin and penicillin V is optimal for the outpatient treatment of cellulitis.
Objectives
To identify and evaluate all randomized-controlled trials (RCTs) comparing oral flucloxacillin alone with a combination of oral flucloxacillin and penicillin V for the outpatient management of cellulitis in the ED setting.
Methods

Criteria for considering studies for this review Types of studies
We planned to include RCTs in all languages in which the target intervention was the ED-based treatment of cellulitis with oral monotherapy or dual therapy. We planned to include trial participants of all ages.
Inclusion criteria
(1) Any RCT in which oral flucloxacillin monotherapy was compared with dual flucloxacillin and penicillin V therapy for the outpatient management of cellulitis in ED patients.
Exclusion criteria
(1) Any RCT in which the intravenous route was used for antibiotic administration in the management of cellulitis. (2) Cross-over trials.
Types of outcome measure
We planned to use the following primary outcomes:
(1) The proportion of patients treated in whom there was a 50% or greater reduction in the maximum diameter of the area of skin infection at the end of the treatment period. (2) Clinical cure or improvement on the basis of symptoms as defined by the trial investigators.
We planned to use the following secondary outcomes:
(1) Clinical relapse as defined by trial investigators.
(2) Change of the initial antibiotic regimen (in terms of the duration of treatment, type, dose or route of antibiotic) because of refractory symptoms of cellulitis.
(3) Quality-of-life scores (including generic SF-36 and disease-specific scores). (4) Mortality.
Search methods for identification of studies Electronic searches
We searched the following three electronic databases with a defined search algorithm on 16 August 2011: The Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library, EBSCO MEDLINE from 1949 to present, and EMBASE 1947 to present.
Ongoing trials
We searched for ongoing trials in the field, most recently in August 2012, in the following electronic databases using the terms 'cellulitis', 'flucloxacillin' and 'penicillin':
( 
Other sources
In addition, we searched a grey literature electronic database (OpenGrey), other medical databases (Current Contents, Science Citation Index), references cited in primary resources, major textbooks in the field of emergency medicine and other unpublished resources known to experts in the specialty (we sought this by personal communication).
Methods of review
Two reviewers (M.Q. and A.W.) assessed the abstract list obtained from each search strategy to identify all potential studies for inclusion. If a study was considered to potentially fulfil the inclusion criteria or if further details were needed to assess the study, the full text was obtained.
Results
Description of studies
The search strategy identified 31 potentially eligible studies from CENTRAL, EMBASE and MEDLINE and 119 potentially eligible studies from our search of other sources ( Fig. 1 ). Three full-text versions of the abstract publications were subsequently retrieved and assessed for inclusion in the review. One full-text version retrieved was a trial that used the intravenous route for antibiotic administration and was therefore excluded [17] . Two reviews of therapy, including one Cochrane review, were retrieved to perform cross-referencing from the reference lists in an attempt to further identify eligible RCTs for inclusion in the review [1, 18] .
Results
Despite a comprehensive literature search, no RCT was identified that fulfilled the inclusion criteria for this review.
In addition, we identified no observational studies that were relevant to the research question using our search criteria.
Discussion
This is the first systematic review aimed at evaluating the evidence base on the use of flucloxacillin monotherapy compared with oral flucloxacillin and penicillin V dual therapy for the outpatient management of cellulitis in the ED setting. Although the literature search performed for this review identified no RCT that fulfilled the predefined inclusion criteria, it identified one ED-based RCT that compared intravenous flucloxacillin monotherapy with intravenous benzylpenicillin and flucloxacillin dual therapy [17] . This RCT found no significant difference between either group in terms of the number of doses of antibiotic required to achieve a clinical response, reduction in the diameter of infection, decrease in temperature and visual analogue pain scale score. In this RCT, after inpatient intravenous antibiotic therapy, the trial participants were discharged from hospital on a 5-day course of oral mono or dual antibiotic therapy that was a continuation of their intravenous in-hospital antibiotic regimen [17] . However, the trial investigators did not follow up the participants after discharge. As this trial examined inpatient, intravenous therapy for treatment, it was not included in this review. Notably, this is the only ED-based RCT of antibiotic therapy for cellulitis that was identified in a recent Cochrane review [1] .
One other retrospective study of 568 admitted inpatients with cellulitis in Northern England showed that the addition of intravenous benzylpenicillin to flucloxacillin had no effect on all-cause mortality at any time point [19] . Not surprisingly, intravenous flucloxacillin alone increased the odds ratio for survival (odds ratio 3.16, P < 0.05). Thus, there is a small evidence base to indicate that the addition of intravenous benzylpenicillin to flucloxacillin for the treatment of uncomplicated cellulitis is probably not necessary.
The case for pencillin-V monotherapy for the prevention of cellulitis recurrence has recently been the subject of two UK-based trials of therapy. The PATCH-1 trial [20] has reported a 45% reduced risk of recurrence of leg cellulitis after treatment for 12 months with penicillin V 250 mg twice daily in patients with two or more previous episodes of leg cellulitis (hazard ratio 0.55, 95% confidence interval (CI) 0.35-0.86). In the PATCH-2 study [21] , which examined patients with one previous episode of leg cellulitis, prophylactic treatment for 6 months with penicillin V reduced the risk of recurrence by 47% (hazard ratio 0.53, 95% CI 0.26-1.07). Although the PATCH-2 trial had difficulty recruiting patients because of a range of factors, there is high-quality evidence that penicillin V monotherapy is effective in preventing recurrence of cellulitis in patients with two or more episodes of infection.
The findings of a recent study from the USA [22] , where the incidence of community-associated, methicillinresistant Staphylococcus aureus (CA-MRSA) as a cause of SSTI has reached epidemic proportions [23] , support the role of b-haemolytic streptococci as an ongoing cause of acute cellulitis. This study found that 73% of cases of nonculturable cellulitis enroled in a large prospective study had positive antistreptolysin O and anti-DNAseB antibodies. Indeed, group A Streptococcus has remained susceptible to penicillin V for over 60 years without signs of antibiotic resistance [24] .
Given that penicillin V clearly plays a role in the treatment of cellulitis, it is perhaps not surprising that oral flucloxacillin and penicillin V are commonly combined in the UK and Ireland for the outpatient treatment of cellulitis [12, 14, 17] . Current practice is probably based on the fact that 'custom and practice' have persisted [12] , and there is perhaps the erroneous idea that 'two antibiotics are better than one' and are therefore prescribed by emergency physicians in an attempt to avert hospital admission. Marwick et al. [25] have recently shown this variation in therapy in which 35 different antibiotic regimens were administered to a cohort of 205 admitted adult patients with SSTI. Notably, there was significant overtreatment of lower severity (CREST group 1) cellulitis.
Given the lack of high-quality evidence available to guide the outpatient therapy of cellulitis, practicing emergency physicians should look to national consensus-based guidelines for direction. Recent UK guidelines recommend monotherapy with flucloxacillin for uncomplicated SSTI presumed to be caused by methicillin-sensitive staphylococci [12, 26] . This is based on the reasoning that higher doses of flucloxacillin also exert antistreptococcal activity [17, 27] and render the coadministration of penicillin V unnecessary. Antibiotic monotherapy also has the advantage of likely improved compliance and lower cost than dual therapy [28] . The most recent Infectious Disease Society of America (IDSA) guidelines [29] lend weight to the traditional teaching that the outpatient treatment of nonpurulent cellulitis should be with antibiotics active against methicillin-sensitive staphylococci and b-haemolytic streptococci, and thus recommend the oral b-lactams dicloxacillin (flucloxacillin) and cephalexin or clindamycin. Abscess-forming infections should be treated with suitable anti-MRSA agents.
European consensus guidelines also generally recommend b-lactam antibiotics for the outpatient treatment of cellulitis. In France, oral amoxicillin is recommended for erysipelas treatable on an outpatient basis [30] . This recommendation is similar to the British Lymphology Society, which also recommend amoxicillin instead of flucloxacillin for patients suffering from lymphoedema with cellulitis [27] . Justification for this is based on superior tissue penetration, a lower minimum inhibitory concentration for amoxicillin and improved side-effect profile.
In Germany, group 1 cephalosporins (cephalexin) are recommended as first-line agents for severe impetigo and furunculosis, and oral clindamycin is recommended as the first-line treatment for mild to moderate cellulitis [3] . For more severe infections, intravenous flucloxacillin or a second-generation cephalosporin is recommended.
Although formal economic evaluation has, to the best of our knowledge, not yet been carried out, flucloxacillin and penicillin V are relatively cheap antibiotics. Nonproprietary flucloxacillin in the UK NHS costs £2.89 for 7 days of treatment and penicillin V costs £1.16 [13] . Despite their relatively low cost, and the high prevalence and healthcare burden of cellulitis, the costs of assessing antibiotic efficacy in a noninferiority RCT would be significantly higher [31] . The majority of NIHR Health Technology Assessment-funded trials cost between £600 000 and £1.2 million (http://www.ncchta.org), which is but one reason why research into the antibiotic treatment of cellulitis has been limited to date.
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Conclusion
There is no published evidence from RCTs to suggest a difference between oral flucloxacillin monotherapy and dual therapy with oral flucloxacillin and penicillin V in the ED-directed outpatient treatment of cellulitis. The results of this review highlight the need for adequately designed and powered RCTs to provide a more robust evidence base for therapeutic decisions on the choice of antibiotic therapy for the ED management of cellulitis on an outpatient basis.
